嵌合抗原受体
汽车T细胞治疗
细胞疗法
T细胞
医学
免疫疗法
遗传增强
生物
T细胞受体
细胞毒性T细胞
免疫学
抗原
细胞
细胞因子释放综合征
免疫系统
遗传学
作者
Haolong Lin,Jiali Cheng,Wei Mu,Jianfeng Zhou,Li Zhu
标识
DOI:10.3389/fimmu.2021.744823
摘要
Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements results in antitumor treatments, especially against hematological malignancies, where it leads to remarkable, long-term antineoplastic effects with higher target specificity. Nevertheless, some limitations persist in autologous CAR-T cell therapy, such as high costs, long manufacturing periods, and restricted cell sources. The development of a universal CAR-T (UCAR-T) cell therapy is an attractive breakthrough point that may overcome most of these drawbacks. Here, we review the progress and challenges in CAR-T cell therapy, especially focusing on comprehensive comparison in UCAR-T cell therapy to original CAR-T cell therapy. Furthermore, we summarize the developments and concerns about the safety and efficiency of UCAR-T cell therapy. Finally, we address other immune cells, which might be promising candidates as a complement for UCAR-T cells. Through a detailed overview, we describe the current landscape and explore the prospect of UCAR-T cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI